FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
|
Thread Tools | Display Modes |
12-03-2010, 11:51 AM | #1 | ||
|
|||
Member
|
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease
http://www.prnewswire.com/news-relea...111255279.html Abraham Lieberman, MD, the study's principal investigator and Director of the Muhammad Ali Parkinson's Center, commented, "NP002 represents an innovative approach to a common side effect in treating Parkinson's disease and has opened up new ideas on how to approach dyskinesias. The early study results of NP002 in patients with Parkinson's show promising trends in reducing dyskinesias and in improving gait. I am encouraged by these results and believe they provide a key piece in understanding and addressing the mechanism of dyskinesias in many of our patients with Parkinson's disease." |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Knopp Neurosciences Presents Results of Phase 1 Ascending Single-Dose Study of KNS-76 | ALS News & Research | |||
New Treatment For Parkinson's Disease Shows Dramatic Results in First Study: | Parkinson's Disease | |||
Positive Results of Phase 3 Study of Fampridine-SR on walking | Multiple Sclerosis |